2017 International Congress Archives - Page 53 of 155

Tacrolimus induced parkinsonism presenting as freezing of gait and speech

V. Paramanandam, H. DS, P.C. N (Chennai, India)
TANDEM REPEATS BEYOND THE CLINICAL DIAGNOSIS IN ADCAs

A. Srivastava, M. Faruq, S. Shakya, I. Singh, V. Swarup (New Delhi, India)
Tandem Standing

E. Okuyucu, E. Dogru Huzmeli, S. Colakoglu Yesildag, I. Huzmeli (Hatay, Turkey)
Tardive Dyskinesia by Body Region in Subjects with Schizophrenia/Schizoaffective Disorder or Mood Disorder: Findings from the KINECT 3 Study

S. Factor, M. Stacy, J. Burke, C. Yonan, H. Le, G. Liang (Atlanta, GA, USA)
Tardive syndromes induced by coadministration of tramadol and sertralin

H. Sarac, N. Bozina, N. Henigsberg, L. Bagaric-Krakan (Zagreb, Croatia)
Targeted overexpression of A53T-alpha-synuclein induces progressive neurodegeneration and electrophysiological changes of noradrenergic locus coeruleus neurons – a preclinical model of Parkinson’s disease

M. Henrich, L. Matschke, A. Stoehr, W.-H. Chiu, B. Lee, F. Geibl, J. Koprich, N. Decher, W. Oertel (Marburg, Germany)
Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease

E. Tsika, E. Gabellieri, A. Davranche, C. Boudou, M. Ravache, L. Grasso, S. Nampally, H. Haddouk, J. Wettstein, A. Pfeifer, A. Muhs (Lausanne, Switzerland)
Targeting the intracellular localization of Ataxin-3 as novel treatment strategy for Spinocerebellar Ataxia Type 3

T. Schmidt, Z. Wang, A. Sowa, J. Schmidt, M. Anders, M.I. Martins, A. de Castro, D. Weishäupl, J. Weber, H. Tricoire, P. Maciel, O. Riess (Tuebingen, Germany)
Tau Network Genes in a Genome Wide Association Study of Progressive Supranuclear Palsy

T. Chang (Los Angeles, CA, USA)
Tau predicts cognitive impairment in a prospective longitudinal CSF study in Parkinson’s Disease

S. Lerche, I. Wurster, O. Hanson, B. Roeben, C. Schulte, T. Gasser, H. Zetterberg, D. Berg, W. Maetzler, K. Brockmann (Tuebingen, Germany)
Tear tumor necrosis factor-alpha levels in patients with Parkinson’s disease: The effect of deep brain stimulation

B. Kocer, S. Comoglu, H. Guven, M. Acar, G. Ozturk (Ankara, Turkey)
TETRAS applicability and study design in randomized, placebo controlled clinical trial of Cav3 modulation for essential tremor patients.

Y. Maricich, E. Newbold, R. Elble (Charlottesville, VA, USA)
The 3-step clinical prediction tool for falls in Parkinson’s disease: can it be used as a self-assessment measure?

L. Mewburn, N. Allen, R. Adams, C. Canning (Lidcombe, Sydney, Australia)
The Accreditation and Certification of the Movement Disorders Subspecialty

S. O'Shea, L. Gutmann, L. Faulkner (New York, NY, USA)
The Adult Spasticity International Registry (ASPIRE) Study: 1 Year Results

G. Francisco, D. Bandari, G. Bavikatte, W. Jost, A. Manack Adams, J. Largent, A. Esquenazi (Houston, TX, USA)
The Adult Spasticity International Registry (ASPIRE) Study: Treatment Utilization Patterns in Patients Treated for Both Upper and Lower Limb Spasticity

G. Francisco, D. Bandari, G. Bavikatte, W. Jost, A. Manack Adams, J. Largent, A. Esquenazi (Houston, TX, USA)
The AppTUG : a new application for analyzing the Timed Up and Go task in patients with neurological disorders

G. Yahalom, Z. Yekutieli, S. Korn-Israeli, S. Elincx-Benizri, V. Livneh, T. Fay-Karmon, Y. Rubel, S. Hassin-Baer (Ramat-Gan, Israel)
The association between motor laterality and cognitive impairment in Parkinson’s disease

J.S. Kim, J.W. Cho, J. Youn (Seoul, Republic of Korea)
The autonomic nervous system in Friedreich´s Ataxia: preliminary findings

E. Indelicato, A. Fanciulli, J. Wanschitz, W. Nachbauer, W. Poewe, G. Wenning, S. Boesch (Innsbruck, Austria)
The battery longevity of implantable pulse generators (IPG) in Parkinson’s disease (PD) is affected by IPG model, number of previous IPG replacements and stimulation energy delivered.

S. Israeli-Korn, T. Fay-Karmon, S. Tessler, G. Yahalom, S. Benizri, H. Strauss, Z. Zibly, R. Spiegelmann, S. Hassin (Ramat Gan, Israel)
The brain plasticity for controlling reach-to-grasp functions of Parkinson’s disease

J. Tretriluxana, S. Tretriluxana, J. Thanakamchokchai, A. Nanbancha, A. Pisarnpong (Nakhon Pathom, Thailand)
The Cats & Dogs Test: a web-based platform to detect early visual processing deficits in Parkinson’s disease

R. Weil, B. Bahrami, D. Schwarzkopf, I. Pavisic, K. Pappa, R. Schade, H. Morris (London, United Kingdom)
The clinical and neuroimaging analysis in hemifacial spasm with associated cranial neuropathy: retrospective case series study

Y.-Y. Chang, Y.-F. Chen, Y.-F. Chen, M.-Y. Lan, J.-S. Liu (Kaohsiung, Taiwan)
The clinical phenotype of progressive supranuclear gaze palsy with predominant cerebellar ataxia (PSP-C): a case series

Z. Xu, T. Lim, W.L. Au, L. Tan (Singapore, Singapore)
The clinical profile associated to Amyloid-beta 42 and Tau cerebrospinal fluid levels in non-demented PD patients

I. Liepelt-Scarfone, F. Klumpp, W. Maetzler, S. Nussbaum, M. Timmers, G. Salvadore, K. Brockmann, T. Gasser, S. Becker, J. Streffer, D. Berg (Tübingen, Germany)
The clinically-available anti-depressant mirtazapine alleviates both psychosis and dyskinesia in the MPTP-lesioned marmoset

I. Frouni, S. Nuara, N. Veyres, C. Kwan, M.-J. Harraka, V. Nafade, L. Sid-Otmane, J. Gourdon, H. Adjia, P. Huot (Montreal, QC, Canada)
The combination of clinical scales and walking measures to predict falls in Parkinson’s disease: Does the length of the prospective follow-up period matter?

R. Vitório, R. Moraes, A. Baptista, E. Lirani-Silva, L. Simieli, D. Orcioli-Silva, F. Barbieri, L. Gobbi (Rio Claro, Brazil)
The combination of the MIBG myocardial scintigraphy and DATSPECT contributes to the diagnosis of PD and other related disorders.

S. Tada, H. Ohtsubo, Y. Yamanishi, N. Miyaue, R. Ando, H. Yabe, N. Nishikawa, M. Nagai, M. Miyagawa, M. Nomoto (Ehime, Japan)
The comparison of urine microvesicle reflecting gut microbiome between Parkinson’s disease and healthy control

J. Park, S. Park, W. Jang, J.S. Kim, J. Yoon, E. Oh (Busan, Republic of Korea)
The complex relationship between olfactory and cognitive impairment in Parkinson’s disease

J. Djordjevic, N.S. Saadat, A. Sadikot, T. White (Montreal, QC, Canada)
The Corticobasal Degeneration Functional Rating Scale (CBD-FS)

A. Lang, G. Stebbins, A. Boxer (Toronto, Canada)
The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine

K. Romero, D. Conrado, B. Corrigan, K. Tsai, M. Ahamadi, S. Macha, V. Sinha, I. Watson, M. Bani, P. Muglia, V. Kern, C. Williams-Gray, D. Grosset, M. Hu, D. Burn, R. Lawson, K. Marek, A. Roach, D. Stephenson, T. Nicholas (Tucson, AZ, USA)
The DBS response ratio: An individual benchmark parameter of DBS quality

L. Lange, M. Reich, R. Nickl, F. Steigerwald, C. Matthies, J. Volkmann (Wuerzburg, Germany)
The diagnostic challenges of patients with possible multiple system atrophy

M. Gultekin, R. Baydemir, M.F. Gol, M. Mirza (Kayseri, Turkey)
The diagnostic dilemma of olivopontocerebellar atrophy and spinocerebellar ataxia, a comparative analysis of clinical cases.

S. Gazieva, O. Turgunkhujaev (Tashkent, Uzbekistan)
The effect and mechanism of acupuncture for pain in Parkinson’s disease

S.-W. Yu, Y.-R. Wu, J.-J. Wang, C.-C. Tsai (Taoyuan, Taiwan)
The Effect of Anxiety on Cognition in Parkinson’s Disease

S. Anderson, G. Stebbins, B. Bernard, A. Negron, J. Goldman (Chicago, IL, USA)
The effect of dance and Nordic Walking on balance, gait and motor function in Parkinson’s disease

J. Stożek, M. Rudzińska, I. Staszczak-Gawełda, A. Stenwak, K. Świątek, S. Podsiadło, U. Pustułka-Piwnik, A. Szczudlik (Krakow, Poland)
The effect of deep brain stimulation in a computational model of essential tremor

N. Yousif, M. Mace, N. Pavese, S. Al-Rasheed, R. Borisyuk, P. Bain, D. Nandi (Hatfield, United Kingdom)
The effect of early STN-DBS in PD patients on axial symptoms: a 2-year randomized controlled trial (EARLYSTIM-Gait analysis)

M. Barbe, L. Tonder, F. Sixel-Döring, B. Debû, L. Timmermann, A. Schnitzler, C. Schade-Brittinger, J. Rau, P. Krack, J.-L. Houeto, M. Schüpbach, G. Deuschl (Cologne, Germany)
The effect of expectation on Parkinson’s Disease: an EEG study

E. Carlino, A. Piedimonte, G. Guerra, A. Romagnolo, E. Frisaldi, S. Vighetti, L. Lopiano (Turin, Italy)
The Effects of Contingency-based Musical Gait Feedback on Cognition in Individuals with Parkinson’s disease: An Interim Analysis

J. Burt, E. Ravid, S. Bradford, N. Fisher, Y. Zeng, B. Hu, R. Camicioli (Edmonton, AB, Canada)
The effects of dual task on the finger tapping performance of Parkinson’s disease.

A. Miyake, T. Yamamoto, H. Kawasaki, T. Furuya, T. Fukuoka, K. Takahashi, N. Tamura, N. Araki (irumagun moroyama town, Japan)
The effects of wearing usual indoor and outdoor footwear on balance and gait performance in people with Parkinson’s disease using clinical tests and instrumented movement analysis.

D. Kunkel, M. Burnett, L. Mamode, R. Pickering, C. Bowen, D. Bader, J. Robison, M. Donovan-Hall, M. Cole, A. Ashburn (Southampton, United Kingdom)
The efficacy of continuous apomorphine infusion in advanced PD patients with cognitive impairments

R. Borgemeester, T. van Laar (Groningen, Netherlands)
The environmental and genetic risk factors in multiple system atrophy in a Taiwanese population

M.-C. Kuo, Y.-C. Lu, M.-L. Chen, C.-H. Tai, C.-H. Lin, R.-M. Wu (Taipei, Taiwan)
The FDA is listening: Integrating the voice of the patient in drug development for Parkinson’s and Huntington’s diseases.

D. Stephenson, A. Porter, K. Romero, G. Podskalny, E. Bastings, B. Dunn, S. Goldstein, T. Mullin (Tucson, AZ, USA)
The French version of the Munich Dysphagia Test-Parkinson’s disease (MDT-PD): Translation and validation in a multilingual population of the Luxembourg Parkinson’s Study (HELP-PD).

G. Hipp, M. Vaillant, M. Gantenbein, M. Kerschenmeyer, P. Kolber, C. Stallinger, K. Roomp, L. Longhino, A. Schweicher, R. Krüger, J. Simons (Belvaux, Luxembourg)
The hardest symptoms that bother patients with Parkinson’s disease

V. Vuletic (Rijeka, Croatia)
The highly-selective metabotropic glutamate receptor 2 positive allosteric modulator LY-487,379 alleviates psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset

L. Sid-Otmane, S. Nuara, A. Hamadjida, N. Veyres, C. Rouillard, M. Panisset, J. Gourdon, P. Huot (Montreal, QC, Canada)
The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

C. Kwan, I. Frouni, V. Nafade, D. Gagnon, M.-J. Wallman, L. Sid-Otmane, M. Parent, A. Parent, C. Rouillard, H. Adjia, P. Huot (Montreal, QC, Canada)
The Huntington’s Disease Health Index Study (HD-HI)

A. Glidden, E. Luebbe, M. Elson, S. Goldenthal, R. Dorsey, C. Heatwole (Rochester, NY, USA)
The identification of molecular-genetic background of familial atypical parkinsonism in “Hornacko”, a specific region of the south-eastern Moravia, Czech Republic.

K. Mensikova, R. Vodicka, K. Kolarikova, T. Bartonikova, P. Kanovsky (Olomouc, Czech Republic)
The Impact of Cognitive Changes on Everyday Life for People with Parkinson’s: The Patient’s Perspective

J. Wertheimer, A. Gottuso, A. Duboille, M. Tuchman, C. Walton (Los Angeles, CA, USA)
The impact of divided attention in dual task conditions on drooling in Parkinson’s Disease (PD): a pilot study

H. Reynolds, N. Miller, R. Walker (Gateshead, United Kingdom)
The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease

M. Nagai, M. Kubo, H. Iwaki, R. Ando, M. Nomoto (Ehime, Japan)
The impact of intensive voice treatment on swallowing in Parkinson disease

D. McFarland, L. Ramig, B. Martin-Harris, K. Humphries, J. Logemann, K. Freeman, A. Halpern, J. Spielman (Montréal, QC, Canada)
The impact of Parkinson’s disease on faith and spirituality

A. Weldehana (Addis Ababa, Ethiopia)
The Importance of Ultrasonographic Evaluation in the Diagnosis of Dysphagia in Parkinson Disease

E. Umay, E. Ozturk, I. Gundogdu, O. Delibas, B. Gonenli, A. Cakci (Ankara, Turkey)
The influence of LRRK2 mutations on cholinergic system in manifest and prodromal stage of Parkinson’s disease: a positron emission tomography study

S. [email protected], D. Wile, J. Fu, J. Valerio, E. Shahinfard, S. McCormick, R. Mabrouk, N. Vafai, J. McKenzie, N. Neilson, A. Perez-Soriano, J. Arena, M. Cherkasova, J. Zhang, C. Zabetian, J. Aasly, Z. Wszolek, M. McKeown, V. Sossi, A. Stoessl (Beijing, China)
The influence of neurorehabilitation on Parkinson medication

V. Tomantschger, A. Tautscher-Basnett, M. Freimueller (Hermagor, Austria)
The influence of sleep disordered breathing in REM sleep behavior disorder associated symptoms

P. Bugalho, M. Mendonça, M. Salavisa, R. Barbosa (Lisbon, Portugal)
The involvement of primary olfactory cortex in olfactory deficits in early-stage Parkinson’s disease

J. Wang, T. Subramanian, Q. Yang (Hershey, PA, USA)
The landscape of interventional trials in Parkinson disease: A 10-year review of ClinicalTrials.gov between 2006 and 2016

K. Wyant, E. Yasuda, V. Kotagal (Ann Arbor, MI, USA)
The Life Style and Risk of Parkinson Disease

R. Pinzon (Yogyakarta, Indonesia)
The Long-Term Safety of Deutetrabenazine for Chorea in Huntington Disease

S. Frank, C. Vaughan, D. Stamler, D. Oakes, M. Davis, S. Eberly, E. Kayson, J. Whaley, J. Goldstein, C. Testa (Boston, MA, USA)
The management of Parkinson’s disease in the Middle East countries: the MDS-middle east task force survey

H. Khalil, Z. Aldaajani, S. Baudry, M. Abualmelh, T. Mohammad, M. Salari, M. Bhatt, S. Tabbal, N.A. Syed, B. Jeon, C. Goetz, J.A. Bajwa (Irbid, Jordan)
The nature of postural tremor in Parkinson’s disease

M. Dirkx, H. Zach, M. Hallet, R. Helmich (Nijmegen, Netherlands)
The neural correlates of apathy in premanifest and manifest Huntington’s disease: A cross-sectional multimodal imaging study

S. Martinez-Horta, J. Perez-Perez, F. Sampedro, M. Carceller, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)
The non-motor symptoms in Parkinsons’s disease patients treated with STN DBS: the follow up study

M. Mencinger, M. Červek, T. Rus, G. Jakob, D. Georgiev, D. Flisar, R. Rajnar, M. Benedičič, K. Boetzel, J. Mehrkens, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)
The Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale for use in Sweden

P. Hagell, M. Nilsson, R. Chaudhuri, P. Odin (Kristianstad, Sweden)
The novel Parkinson´s disease locus RIT2 and alpha-synuclein function in intersecting pathways

M. Volta, J. Obergasteiger, C. Überbacher, C. Ascione, C. Corti, A. Hicks, P. Pramstaller (Bolzano, Italy)
The occurrence of dopamine-responsive and dopamine-resistant resting tremor in Parkinson’s disease

H. Zach, M. Dirkx, D. Roth, j. Pasman, B. Bloem, R. Helmich (Nijmegen, Netherlands)
The Personal Kinetigraph Fluctuator Score Identifies Motor Fluctuations in Parkinson’s disease

E. Tan, M. Tagliati, E. Hogg, M. Horne (Los Angeles, CA, USA)
The phenotypic spectrum of patients with progressive supranuclear palsy

M. Gultekin, R. Baydemir, M.F. Gol, M. Mirza (Kayseri, Turkey)
The predictor factors for survival in Chinese Multiple System Atrophy patients

B. Cao, L. Zhang, Y. Zou, Q. Wei, R. Ou, Y. Chen, J. Yang, Y. Wu, H. Shang (Chengdu, China)
The predominant parkinsonian phenotype in beta propeller associated neurodegeneration (BPAN)

H. Morales, B. Sanchez-Hernandez, R. Leal-Ortega, M. Rodriguez-Violante, M. Kurian, V. Fung (Westmead, NSW, Australia)
The prevalence of cerebral microbleeds in patients with Parkinson’s disease and multiple system atrophy

J.-M. Kim (Seongnam, Republic of Korea)
The Pull Test in healthy subjects and Parkinson´s disease: quantitative pull-force measure, postugraphic and electromyographic analysis

J.R. Perez-Sanchez, B. DeLaCasa-Fages, A. Contreras, J.M. Velázquez, A. Muñoz-González, F. Grandas (Madrid, Spain)
The Putamen to Caudate Nucleus Ratio: A Simple Surrogate Marker for Dopaminergic Volume in Putamen

J.J. Lee, Y.H. Sohn (Goyang-si, Republic of Korea)
The Relationship between Olfactory Function and Clinical Subtypes of Parkinson’s Disease

D.-Y. Kwon (Ansan, Republic of Korea)
The Relative Preservation of the Dopaminergic Neuroal Loss of Patients with Parkinson’s Disease Having Dopamine-Unresponsive Resting Tremor

S. You, H.W. Kim (Daegu, Republic of Korea)
The Role of Clinical Outcome Assessment (COA) Data in the Drug Approval Process of Medicines for the Treatment of Restless Legs Syndrome (RLS): A Review of the Labels of Medicines Approved by the FDA and the EMA

M.-P. Emery, C. Anfray, L.-L. Perrier, C. Acquadro (Lyon, France)
The role of habenula and amygdala dysfunction in Parkinson’s disease patients with punding

V. Markovic, F. Agosta, E. Canu, A. Inuggi, I. Petrovic, I. Stankovic, F. Imperiale, T. Stojkovic, V. Kostic, M. Filippi (Belgrade, Serbia)
The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report

A. Tran, M. Amin, R. Burns (Phoenix, AZ, USA)
The role of phosphodiesterase 4 in sleep disturbances in Parkinson’s disease

H. Wilson, G. Pagano, F. Niccolini, N. Muhlert, C. Coello, M. Mehta, G. Searle, R. Gunn, E. Rabiner, T. Foltynie, M. Politis (London, United Kingdom)
The Role of Social Work in Improving Comprehensive Care for Parkinson’s Disease

E. Book, A. Lemen (Vancouver, BC, Canada)
The Roles of Diet, Exercise, & Supplements in Parkinson’s Disease Progression

L. Mischley, R. Lau (Kenmore, WA, USA)
The secular change of quality of life in patients with Parkinson’s disease.

A. Kumon, M. Saruwatari, N. Kawashima, K. Hasegawa (Sagamihara, Japan)
The spectrum of composite autonomic severity score in SCA1, SCA2 and SCA3 patients

D. Tamuli, A. Godiyal, A. Jaryal, A. Srivastava, K. Deepak (New Delhi, India)
The spectrum of Pantothenate kinase-associated neurodegeneration.A view from seven cases Cohort.

E. Guartazaca Guerrero, J. Llibre Guerra, A. Soto Lavastida, A. Rodriguez Salgado, G. Bringas, J. Diaz Marante (Cuenca, Ecuador)
The Study of Deep Brain Stimulation of Globus Pallidus Internus for Refractory Tourette Syndrome

M. Zhao, Y. Guan, J. Zhou (Beijing, China)
The Superior Colliculus is impaired in de novo Parkinson’s disease patients

E. BELLOT, E. BELLOT, V. COIZET, S. MEONI, P. PELISSIER, B. DEBU, M. DOJAT, E. MORO (LA TRONCHE, France)
The SYNAPSES study (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): methodology and results from the European feasibility survey

G. Camattari, G. Abbruzzese, W. Jost, J. Kulisevsky, V. Tubazio, L. Simoni, The SYNAPSES investigators (Bresso, Italy)
The therapeutic effect of MANF in the MPTP/MPP+-induced model of Parkinson’s disease

y. liu (shanghai city, China)
The therapeutic effects of cortical electrical stimulation in an animal model of Parkinson’s disease

T.-H. Hsieh, W.-S. Chang Chien, C.-W. Peng, Y.-Z. Hunag, J.-J. Chen (Taoyuan, Taiwan)
The tricyclic antidepressant medication nortriptyline inhibits alpha-synuclein accumulation, aggregation and toxicity in multiple in vitro and in vivo models.

T. Collier, L. Lapidus, C. Sortwell, C. Justman, P. Lansbury, K. Paumier (Grand Rapids, MI, USA)
The Use of Atypical Antipsychotics in Depression and Anxiety may Unmask Parkinson’s Disease: A Retrospective Chart Review

K. Amodeo, R. Schneider, I. Richard (Rochester, NY, USA)
The utility of post-void residual volume versus sphincter electromyography to distinguish between multiple system atrophy and Parkinson’s disease

T. Yamamoto, M. Asahina, Y. Yamanaka, T. Uchiyama, S. Hirano, M. Fuse, Y. Koga, R. Sakakibara, S. Kuwabara (Chiba, Japan)
The value of classical cerebrospinal fluid protein ratios and peripheral inflammation in Parkinson’s disease cognitive impairment

M. Delgado-Alvarado, R. Dacosta-Aguayo, I. Navalpotro-Gómez, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergareche, J. Martí-Massó, M. Rodríguez-Oroz (San Sebastián, Spain)
The Value of Follow Up: The Role of Social Work and Nursing Calls in an Interdisciplinary Home Visit Program for Advanced Parkinson’s Disease Patients

S. Oyler, M. Sweeney, A. Lemen, A. Di Rocco, J. Fleisher (New York, NY, USA)
The value of the Tau/α-synuclein ratio and TNF-α in cerebrospinal fluid, and of plasma IL-6, in the diagnosis and prognosis of Parkinson’s disease

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jimenez-Urbieta, R. Dacosta-Aguayo, I. Navalpotro-Gómez, J. Ruiz-Martínez, A. Bergareche, J. Martí-Massó, P. Martínez-Lage, A. Izagirre, M. Rodríguez-Oroz (San Sebastián, Spain)
The value of various risk factors in the manifestation of Parkinson’s disease in the southern part of Uzbekistan.

S. Lukmonov (Tashkent, Uzbekistan)
The Volatility of Local Field Potential Oscillations in Dystonia and Parkinson’s disease

D. Pina Fuentes, J. van Zijl, J.-W. Elting, G. Drost, M. van Egmond, M. Oterdoom, M. Tijssen, M. van Dijk, M. Beudel (Groningen, Netherlands)
Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations

J. Mitsui, K. Koguchi, T. Momose, M. Takahashi, T. Matsukawa, T. Yasuda, S.-i. Tokushige, H. Ishiura, J. Goto, S. Nakazaki, T. Kondo, H. Ito, Y. Yamamoto, S. Tsuji (Tokyo, Japan)
Tic Severity and Treatment in Children: The Effect of Comorbid Attention Deficit Hyperactivity Disorder and Obsessive Compulsive Behaviours

T. Pringsheim (Calgary, AB, Canada)
Tics Exacerbations in Adults with Tic Disorders: A Case series

S. Schaefer, C. Chow, E. Louis, D. Robakis (New Haven, CT, USA)
Time to retreatment with botulinum toxin A in upper limb spasticity management: initial data from the Upper Limb International Spasticity (ULIS)-III study

L. Turner-Stokes, S. Ashford, J. Jacinto, K. Fheodoroff, G. Suarez, P. Maisonobe (London, United Kingdom)
TMEM230 mutation analysis in Parkinson’s disease in a Chinese population

Z. Liu (Changsha, China)
To Study the Role of Biomarkers DJ-1 and Apo A1 in Idiopathic Parkinson’s Disease and Parkinson Plus Syndromes in Indian Population

M. Modi, R. Shree, S. Mehta, M. Goyal, B. Medhi, V. Lal, B. Mittal (Chandigarh, India)
Tongue strength in Parkinson’s disease.

H. Kalf, J. van Asperen, F. Tuenter, L. van Vucht, J. Vanderwegen, G. van Nuffelen (Nijmegen, Netherlands)
Tongue Strength in PSP

H. Clark, J. Whitwell, J. Ahlskog, K. Josephs (Rochester, MN, USA)
Tonsillectomy and risk of Parkinson’s disease: A Danish nationwide population-based cohort study

E. Svensson, V. Henderson, S. Szépligeti, M. Stokholm, T. Klug, H. Sørensen, P. Borghammer (Aarhus, Denmark)
Topography of essential tremor

W. Chen, F. Hopfner, S. Szymczak, O. Granert, S.H. Müller, G. Kuhlenbäumer, G. Deuschl (Shanghai, China)
Tourettism associated with the Xq25 Microduplication Syndrome

C. Spears, I. Malaty (Gainesville, FL, USA)
Towards a reappraisal of Status Dystonicus : a cohort study

X. VASQUES, E. Nerrant, V. GONZALEZ, C. MILESI, N. MENJOT, G. CAMBONIE, J. PEREZ, A. Bonafe, P. Coubes, L. CIF (Montpellier, France)
Towards Responsive Deep Brain Stimulation for Medically Refractory Freezing of Gait in Parkinson’s Disease

R. Molina, J. Shute, E. Opri, K. Sowalsky, J. Roper, D. Martinez-Ramirez, K. Foote, C. Hass, M. Okun, A. Gunduz (Gainesville, FL, USA)
Tozadenant phase 3 study (TOZ-PD) in Parkinson’s disease patients with motor fluctuations: baseline characteristics

K. Kieburtz, W. Olanow, J. Krishnaswami, C. Resburg, F. Kerwood, C. Kenney (Rochester, NY, USA)
Transcranial direct current stimulation enhances consolidation of learning in Parkinson’s disease

S. Broeder, E. Nackaerts, E. Heremans, K. Cuypers, R. Meesen, G. Verheyden, A. Nieuwboer (Leuven, Belgium)
Transcranial sonography in the prognosis of drug-induced parkinsonism

Y.-S. Oh, D.-Y. Kwon (Seoul, Republic of Korea)
Transient loss of psychic self-activation following bilateral thalamic ventral intermediate nucleus stimulation for essential tremor

C. Marques-Matos, L. Braz, P. Monteiro, M. Mota-Oliveira, C. Reis, P. Linhares, R. Vaz, M.J. Rosas (Porto, Portugal)
Translating the Parkinson´s Disease Sleep Scale (PDSS-2) into 31 Languages Using a Standardized Methodology

K.R. Chaudhuri, C. Trenkwalder, C. Anfray, M.-P. Emery, C. Acquadro (London, United Kingdom)
Translating the Rapid Eye Movement (REM) Sleep Behavior Disorder Screening Questionnaire (RBDSQ) into 21 Languages Using a Standardized Methodology

M.-P. Emery, C. Anfray, K. Stiasny-Kolster, C. Acquadro (Lyon, France)
Translation and validation of the Filipino version of the wearing-off questionnaire-19 (F-WOQ-19)

K. Remigio, R.D. Jamora (Manila, Philippines)
Treadmill training, Tai Chi, dance and more: a meta-analysis on the effectiveness of different physiotherapy modalities in Parkinson’s disease

D. Radder, N. de Vries, M. Faber, M. van Nimwegen, S. Keus, B. Bloem (Nijmegen, Netherlands)
Treatable Rare Movement Disorders

E. Gatto, H. Jinnah, A. Espay, J. Jankovic, K. Bhatia, M. Rodriguez, V. Fung, F. Cardoso, M. Rodriguez Oroz, A. Albanese, A. Muenchau, A. Chade, M. de Koning-Tijssen, M. Stamelou, P. Garcia Ruiz, C. Uribe Roca, F. Morgante, A. Dela Cerda, L. Schoels, J. Miyasaki, J. Ferreira (Buenos Aires, Argentina)
Treatment associated improvement in motor scores is not reflected in improvement in hand dexterity in Parkinson’s disease patients

S. Filipović, A. Kačar (Beograd, Serbia)
Treatment of back pain in patient with extensor truncal dystonia with lumbar radiofrequency ablation (RFA)

S. Giles, N. Shneyder, J. Cupido, C. Brock, E. Gaitour (Jacksonville, FL, USA)
Treatment of Functional Neurological Disorders: Towards Expert Consensus Led Guidelines for the American Neuropsychiatric Association Committee for Research

O. Ghaffar, M. Modirrousta, C. LaFrance, N. Williams, R. Shura, S. Ducharme, V. Voon (Whitby, ON, Canada)
Treatment of Parkinson’s disease psychosis–a systematic review of RCTs

K. Cook, D. Nellesen, K. Adamski, A. Shim (Menlo Park, CA, USA)
Treatment of Psychosis in Parkinson’s Disease: Evidence-Based Recommendations Versus Actual Clinical Practice

L.G. Chan, A. Kong, L. Tan (Singapore, Singapore)
Treatment of secondary movement disorders related to midbrain cavernomas

K. Karpinska, A. Smolanka (Uzhgorod, Ukraine)
Treatment Outcomes for Deep Brain Stimulation in Sex-Linked Dystonia Parkinsonism (XDP, DYT3) Up To 60 Months Follow-up – A Case Series

J.E. Abejero, J. Aguilar, T. Vesagas, R. Teleg, J. Anlacan, R.D. Jamora (Manila, Philippines)
Tremor as the first symptom reported by Parkinson’s disease patients is a predictor of future motor subtype and levodopa-induced dyskinesia.

A. Schumacher-Schuh, F. Drumond, J. Leal, M. Dotto, S. Machado, C. Rieder (Porto Alegre, Brazil)
Tremor Characteristics in Essential Tremor and Dystonic Tremor

P. Panyakaew, H.J. Cho, M. Hallett (Bangkok, Thailand)
Tremor in motorneuron disease: central or peripheral origin?

A. Latorre, M. Stamelou, L. Rocchi, M. Ciocca, K. Sidle, J. Rothwell, K. Bhatia (London, United Kingdom)
Tremor-Dominant Clinical Phenotype is Associated with Low Risk of Levodopa-Induced Dyskinesia in Parkinson’s Disease

B. Santos-Lobato, M. Capelari, N. Novaretti, Â. Vieira, V. Borges, H. Ferraz, I. Mata, C. Zabetian, V. Tumas (Ribeirão Preto, Brazil)
Tremor’s Glove – An Innovative Electrical Muscle Stimulation Therapy to Treat Intractable Tremor in Parkinson’s Disease Patients: A Randomized Sham-Controlled Trial

O. Jitkritsadakul, C. Thanawattano, C. Anan, R. Bhidayasiri (Bangkok, Thailand)
Trisomy 8 Mosaicism and dystonia: a THAP1 overdose?

A. Fois, M. Tchan, V. Fung (Westmead, Australia)
Twiddler Syndrome in Deep Brain Stimulation

N. Durmaz Celik, M. Vural, S. Ozkan (Eskişehir, Turkey)
Two ethnic clusters with Huntington’s disease in Israel – The case of Mountain Jews and Karaites

J. Zitser, A. Thaler, N. Inbar, S. Naor, N. Giladi, T. Gurevich (Tel Aviv, Israel)
Two patients with dystonia treated with internal globus pallidus deep brain stimulation (GPi-DBS) using a multiple independent source current-controlled system,long term results,a case report 

O. Morsi, J. Jimenez, J. Lopez, B. Cuartero, J. Zamarro, R. Sanchez, M. Felipe, J.J. Martin (Murcia, Spain)
Two sides of a Rare Coin- First report of Rapid onset dystonia-parkinsonism (RDP) and Alternating Hemiplegia of Childhood (AHC) with paroxysmal dystonia from India.

P. Agarwal, S. Ravat (Mumbai, India)
Two-year prospective study reveals that gut dysbiosis predicts progression of Parkinson’s disease

M. Hirayama, T. Minato, Y. Fujisawa, H. Tsuji, T. Asahara, K. Nomoto, T. Maeda, K. Ohno (Nagoya, Japan)
Tyrosine kinase inhibition clears Tau and reserves neuropathology and motor symptoms in a novel model of progressive supranuclear palsy

Y. Torres-Yaghi, F. Pagan, A. Lawler, T. Kimbason, N. Starr, B. Wilmarth, M. Arellano, M. Javidnia, M. Hebron, C. Moussa (Washington, DC, USA)